Active Ingredient History
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumor (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mechanistic target of rapamycin (mTOR) kinase inhibitor that reduces the sensitivity of T cells and B cells to interleukin-2 (IL-2), inhibiting their activity. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acne Vulgaris (Phase 2)
Adenomatous Polyposis Coli (Phase 2)
Aging (Early Phase 1)
Bone Marrow Cells (Phase 1)
Breast Neoplasms (Phase 3)
Carcinoma, Hepatocellular (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 1/Phase 2)
Carcinoma, Squamous Cell (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Phase 1/Phase 2)
Chordoma (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Epigenomics (Early Phase 1)
Genetic Diseases, Inborn (Phase 2)
Gout (Phase 3)
Graft vs Host Disease (Phase 1)
Hodgkin Disease (Phase 1/Phase 2)
Hypertension, Pulmonary (Phase 1)
Hyperuricemia (Phase 2)
Inflammation (Early Phase 1)
Keloid (Early Phase 1)
Leukemia (Phase 1)
Lymphatic Diseases (Phase 2)
Melanoma (Phase 1/Phase 2)
Multiple Myeloma (Phase 1)
Mutation (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 1/Phase 2)
Neoplasms (Phase 1/Phase 2)
Pachyonychia Congenita (Phase 3)
Perivascular Epithelioid Cell Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1)
Sarcoma (Phase 1/Phase 2)
Sarcoma, Ewing (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Vascular Diseases (Phase 2/Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue